This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Wilford B. Neptune, MD

Arch Surg. 1988;123(5):583-585.

Abstract
• We reviewed 100 operations performed on 95 consecutive patients with stage II (n = 7) and stage III (n = 88) primary lung cancer. The five-year survival of patients with N1 involvement was 58% and with N2 disease was 21%. Of 13 patients with Pancoast or chest wall involvement, 58% survived five years. The entire group had a 34% five-year survival and a median survival of 32 months. Preoperative and/or postoperative radiotherapy, in the presence of nodal disease, appears to improve local control, but an effective chemotherapy program is needed for unrecognized visceral metastases. In the absence of contraindications, surgical excision offers the best likelihood of survival and quality of life.

(Arch Surg 1988;123:583-585)

Author Affiliations
From New England Deaconess Hospital, Harvard Medical School, Boston.

Footnotes
Accepted for publication Jan 27, 1988.

Read before the Annual Meeting of the New England Surgical Society, Bretton Woods, NH, Sept 11, 1987.

Reprint requests to Overholt Cardiothoracic Surgical Associates, 135 Francis St, Boston, MA 02215 (Dr Neptune).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?